<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mossj</journal-id><journal-title-group><journal-title xml:lang="ru">Московский хирургический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Moscow Surgical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-3180</issn><publisher><publisher-name>ООО «ПРОФИЛЬ – 2С»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17238/2072-3180-2024-4-106-115</article-id><article-id custom-type="elpub" pub-id-type="custom">mossj-853</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>Мультивисцеральные тазовые резекции при раке яичников: непосредственные результаты</article-title><trans-title-group xml:lang="en"><trans-title>Multivisceral pelvic resections for ovarian cancer: short-term results</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7281-3591</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лядов</surname><given-names>В. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyadov</surname><given-names>V. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Константинович Лядов – доктор медицинских наук, доцент, заведующий отделением онкологии № 4, 117152, Москва, Загородное шоссе, д. 18А;</p><p>профессор кафедры онкологии и паллиативной медицины имени академика И.А. Савицкого, 123242, Москва, Баррикадная ул., 2/1, стр. 1;</p><p>заведующий кафедрой онкологии, 654005, Новокузнецк, просп. Строителей, д. 5</p></bio><bio xml:lang="en"><p>Lyadov Vladimir Konstantinovich – PhD, Head of Division of Oncology № 4, Moscow, 115446;</p><p>Associate Professor at the Chair of Oncology and Palliative Medicine named after Academician I.A. Savitsky, Moscow;</p><p>Head of the Chair of Oncology, Novokuznetsk</p></bio><email xlink:type="simple">vlyadov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2499-6637</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Москаленко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Moskalenko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москаленко Алексей Николаевич – врач-онколог, заведующий операционным блоком,</p><p>117152, Москва, Загородное шоссе, д. 18А</p></bio><bio xml:lang="en"><p>Moskalenko Aleksei Nikolaevich – Oncologist of Division of Oncology № 4,</p><p>115446, Moscow, 117152, Zagorodnoe road, 18A</p></bio><email xlink:type="simple">mansurgkokod@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9282-5509</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гарипов</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Garipov</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гарипов Марат Русланович – врач-онколог онкологического отделения № 4,</p><p>117152, Москва, Загородное шоссе, д. 18А</p></bio><bio xml:lang="en"><p>Garipov Marat Ruslanovich – Oncologist of Division of Oncology № 4,</p><p>115446, Moscow, 117152, Zagorodnoe road, 18A</p></bio><email xlink:type="simple">mar.gari2010@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7054-9440</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Невров</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nevrov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Невров Андрей Сергеевич – ординатор-онколог, кафедры онкологии и паллиативной медицины имени академика И.А. Савицкого,</p><p>123242, Москва, Баррикадная ул., 2/1, стр.  1</p></bio><bio xml:lang="en"><p>Nevrov Andrey Sergeevich – resident, Department of Oncology and Palliative Medicine named after Academician I.A. Savitsky,</p><p>125993, Moscow, Barrikadnaya st., 2/1, bldg 1</p></bio><email xlink:type="simple">andynerv@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5516-7367</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федоринов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorinov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федоринов Денис Сергеевич – врач-онколог отделения химиотерапии, 117152, Москва, Загородное шоссе, д. 18А;</p><p>старший лаборант кафедры онкологии и паллиативной медицины им. академика А.И. Савицкого, 123242, Москва, Баррикадная ул., 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Fedorinov Denis Sergeevich – Oncologist of Division of Chemotherapy,</p><p>117152, Moscow, Zagorodnoe road, 18A</p></bio><email xlink:type="simple">deni_fe@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Онкологический центр № 1 Городской клинической больницы имени С. С. Юдина Департамента здравоохранения города Москвы;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ;&#13;
Новокузнецкий государственный институт усовершенствования врачей — филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow State Budgetary Healthcare Institution «Moscow City Hospital named S.S. Yudina, Moscow Healthcare Department»;&#13;
Russian Medical Academy of Continuous Professional Education;&#13;
Novokuznetsk State Medical Institute for Advanced Training of Physicians</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Онкологический центр № 1 Городской клинической больницы имени С. С. Юдина Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow State Budgetary Healthcare Institution «Moscow City Hospital named S.S. Yudina, Moscow Healthcare Department»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Онкологический центр № 1 Городской клинической больницы имени С. С. Юдина Департамента здравоохранения города Москвы;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow State Budgetary Healthcare Institution «Moscow City Hospital named S.S. Yudina, Moscow Healthcare Department»;&#13;
Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2024</year></pub-date><volume>0</volume><issue>4</issue><fpage>106</fpage><lpage>115</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лядов В.К., Москаленко А.Н., Гарипов М.Р., Невров А.С., Федоринов Д.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Лядов В.К., Москаленко А.Н., Гарипов М.Р., Невров А.С., Федоринов Д.С.</copyright-holder><copyright-holder xml:lang="en">Lyadov V.K., Moskalenko A.N., Garipov M.R., Nevrov A.S., Fedorinov D.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mossj.ru/jour/article/view/853">https://www.mossj.ru/jour/article/view/853</self-uri><abstract><sec><title>Введение</title><p>Введение. В России рак яичников находится на 8 месте в структуре онкологических заболеваний среди женщин.</p></sec><sec><title>Цель</title><p>Цель. Изучить непосредственные результаты мультивисцеральных тазовых резекций при раке яичников и оценить эффективность стандартизированного протокола кровосбережения и периоперационного ведения пациенток.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. С 2018 по 2024 гг. выполнено 50 мультивисцеральных резекций органов малого таза при раке яичников. Возраст составил 57,4±12,9 лет, ИМТ – 27,9±6,4 кг/м2. С целью профилактики осложнений был разработан и внедрен в практику стандартизированный протокол кровосбережения и периоперационного ведения пациенток. Наряду с анестезиологическими компонентами протокол включал в себя применение хирургических луп и отказ от «шейвинга» кишки в пользу удаления пораженных узлами карциноматоза органов единым блоком. Оценка тяжести осложнений проводилась в соответствии с классификацией Dindo-Clavien.</p></sec><sec><title>Результаты</title><p>Результаты. Средняя длительность операций составила 305±99 мин, средний объем кровопотери 242±221 мл, послеоперационная летальность – 0. Всего осложнений II–IVА ст. 42 %. Инфекции области хирургического вмешательства – 20 %. Медиана пребывания в стационаре после операции составила 10,5±9,4 суток. Единственным фактором, оказавшим значимое влияние на частоту развития тяжелых осложнений, стала сложность операции по классификации Aletti: вероятность развития осложнений после «сложных» операций была выше в 7,364 раза (95 % ДИ: 1,671 – 32,440, р=0,007). Объем кровопотери ≥250 мл стал единственным фактором, определявшим высокую вероятность развития инфекционных осложнений.</p></sec><sec><title>Выводы</title><p>Выводы. Применение стандартизированного протокола периоперационного ведения пациенток позволило достичь приемлемого показателя частоты тяжелых осложнений после обширных мультивисцеральных резекций при раке яичников.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate whether blood preservation and a perioperative clinical pathway might reduce the rate of complications after multivisceral pelvic resections in patients with advanced ovarian cancer.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: From 2018 to 2024 we performed 50 multivisceral pelvic resections in patients with advanced ovarian cancer. Age was 57,4±12,9 years, BMI – 27,9±6,4 kg/m2 . We previously developed and implemented a standardized protocol for blood preservation and perioperative management of patients in order to reduce the number of complications after multivisceral pelvic resections. The protocol included meticulous tissue preparation under magnification and en bloc visceral resections instead of gut wall “shaving” apart of anaesthesiological components. The severity of complications was assessed according to Dindo-Clavien classification.</p></sec><sec><title>Results</title><p>Results: Duration of operations was 305±99 min, blood loss constituted 242±221 ml, postoperative mortality – 0. Grade II–IVa complications developed in 42 % of cases, surgical site infection – 20 %. Median hospital stay after surgery was 10,5±9,4 days. The only factor that had a significant impact on the incidence of severe complications was the complexity of the operation according to Aletti (odds ratio 7,364, 95 % CI: 1,671 – 32,440, p = 0,007). The volume of intraoperative blood loss ≥ 250 ml remained the only predictor of infectious complications in multivariate analysis.</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of a standardized perioperative clinical pathway in patients with advanced ovarian cancer allowed us to achieve an acceptable rate of severe postoperative complications after extensive pelvic resections.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак яичников</kwd><kwd>циторедукция</kwd><kwd>циторедуктивная хирургия</kwd><kwd>мультивисцеральная резекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Ovarian Cancer</kwd><kwd>Cytoreductive Surgery</kwd><kwd>Multivisceral resection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 275 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. State of oncological care for the population of Russoa in 2021. Moscow: P.A. Herzen Moscow Scientific and Research Oncological Institute, 2022, pр. 239. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Тюляндина А.С., Коломиец Л.А., Морхов К.Ю., Нечушкина В.М., Покатаев И.А., Румянцев А.А. и соавт. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023. № 3. С. 201–215.</mixed-citation><mixed-citation xml:lang="en">Tjuljandina A.S., Kolomiec L.A., Morhov K.Ju., Nechushkina V.M., Pokataev I.A., Rumjancev A.A., Tjuljandin S.A., Urmancheeva A.F., Hohlova S.V. Ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Zlokachestvennye opuholi, 2023, № 3, pp. 201–215. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Доломанова Е. В., Мавричев С. А., Мириленко Л. В. Анализ результатов комплексного лечения пациенток, страдающих раком яичников III-IV стадий с использованием первичной и интервальной циторедукции. Онкологический журнал, 2020. 14. № 4 (56). С. 41–48.</mixed-citation><mixed-citation xml:lang="en">Dolomanova E.V., Mirilenko L.V., Mavrichev S.A. Primary and interval debulking surgery in complex treatment of advanced ovarian cancer patients: results from systematic single-center retrospective study analysis. Onkologicheskij zhurnal, 2020, № 4 (56), pp. 41–48. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Доломанова Е.В., Мириленко Л.В., Мавричев С.А. Факторы прогноза непосредственных и отдаленных результатов лечения пациенток, страдающих раком яичников IIIС–IV стадий. Репродуктивное здоровье. Восточная Европа, 2021. Том 11. № 2. С. 185–197.</mixed-citation><mixed-citation xml:lang="en">Dolomanova E.V., Mirilenko L.V., Mavrichev S.A. Prognostic factors of short- and long-term outcome in patients with advanced ovarian cancer. Reproductive health. Eastern Europe, 2021, vol. 11, № 2, pp. 185–197. https://doi.org/10.34883/PI.2021.11.2.005</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar A., Janco J.M., Mariani A., Bakkum-Gamez J.N., Langstraat C.L., Weaver A.L., McGree M.E., Cliby W.A. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol., 2016, № 140 (1), рр. 15–21. https://doi.org/10.1016/j.ygyno.2015.10.025</mixed-citation><mixed-citation xml:lang="en">Kumar A., Janco J.M., Mariani A., Bakkum-Gamez J.N., Langstraat C.L., Weaver A.L., McGree M.E., Cliby W.A. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol., 2016, № 140 (1), рр. 15–21. https://doi.org/10.1016/j.ygyno.2015.10.025</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Straubhar A.M., Wolf J.L., Zhou Q.C. и др. Advanced ovarian cancer and cytoreductive surgery: independent validation of a risk-calculator for perioperative adverse events. Gynecologic oncology, 2021, № 160 (2), рр. 438–444. https://doi.org/10.1016/j.ygyno.2020.11.021</mixed-citation><mixed-citation xml:lang="en">Straubhar A.M., Wolf J.L., Zhou Q.C. и др. Advanced ovarian cancer and cytoreductive surgery: independent validation of a risk-calculator for perioperative adverse events. Gynecologic oncology, 2021, № 160 (2), рр. 438–444. https://doi.org/10.1016/j.ygyno.2020.11.021</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Aletti G.D., Podratz K.C., Moriarty J.P., Cliby W.A., Long K.H. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecologic oncology, 2009, № 112 (1), рр. 16–21. https://doi.org/10.1016/j.ygyno.2008.10.008</mixed-citation><mixed-citation xml:lang="en">Aletti G.D., Podratz K.C., Moriarty J.P., Cliby W.A., Long K.H. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.  Gynecologic oncology,  2009, № 112 (1), рр. 16–21. https://doi.org/10.1016/j.ygyno.2008.10.008</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Гарипов М.Р., Москаленко А.Н., Черепанова Е.В., Аюпов Р.Т., Феоктистов Д.В., Тарасов Н.А., Лядов В.К., Галкин В.Н. Протоколы ускоренного выздоровления при расширенно-комбинированных операциях на органах малого таза. Хирургия. Журнал им. Н.И. Пирогова, 2022. № 12 (2). С. 59–65.</mixed-citation><mixed-citation xml:lang="en">Garipov M.R., Moskalenko A.N., Cherepanova E.V., Ajupov R.T., Feoktistov D.V., Tarasov N.A., Lyadov V.K., Galkin V.N. Protocols for accelerated recovery during extended-combined operations on the pelvic organs. Pirogov Russian Journal of Surgery, 2022, № 12 (2), pp. 59–65. (In Russian.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hübner M., Kusamura S., Villeneuve L., Al-Niaimi A., Alyami M., Balonov K., Bell J., Bristow R., Guiral D.C., Fagotti A., Falcão L.F.R., Glehen O., Lambert L., Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar S.P., Wadhwa A., Altman A., Fawcett W., Veerapong J., Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations– Part I: Preoperative and intraoperative management. European Journal of Surgical Oncology,2020, № 46 (12), рр. 2292–2310. https://doi.org/10.1016/j.ejso.2020.07.041</mixed-citation><mixed-citation xml:lang="en">Hübner M., Kusamura S., Villeneuve L., Al-Niaimi A., Alyami M., Balonov K., Bell J., Bristow R., Guiral D.C., Fagotti A., Falcão L.F.R., Glehen O., Lambert L., Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar S.P., Wadhwa A., Altman A., Fawcett W., Veerapong J., Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations– Part I: Preoperative and intraoperative management. European Journal of Surgical Oncology,2020, № 46 (12), рр. 2292–2310. https://doi.org/10.1016/j.ejso.2020.07.041</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hübner M., Kusamura S., Villeneuve L., Al-Niaimi A., Alyami M., Balonov K., Bell J., Bristow R., Guiral D.C., Fagotti A., Falcão L.F.R., Glehen O., Lambert L., Mack L., Muenster T., Piso P., Pocard M., Rau B., Sgarbura O., Somashekhar S.P., Wadhwa A., Altman A., Fawcett W., Veerapong J., Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations— Part II: Postoperative management and special considerations. European Journal of Surgical Oncology, 2020, № 46 (12), рр. 2292–2310. https://doi.org/10.1016/j.ejso.2020.08.006</mixed-citation><mixed-citation xml:lang="en">Hübner M., Kusamura S., Villeneuve L., Al-Niaimi A., Alyami M., Balonov K., Bell J., Bristow R., Guiral D.C., Fagotti A., Falcão L.F.R., Glehen O., Lambert L., Mack L., Muenster T., Piso P., Pocard M., Rau B., Sgarbura O., Somashekhar S.P., Wadhwa A., Altman A., Fawcett W., Veerapong J., Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations— Part II: Postoperative management and special considerations. European Journal of Surgical Oncology, 2020, № 46 (12), рр. 2292–2310. https://doi.org/10.1016/j.ejso.2020.08.006</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Лядов В.К., Гарипов М.Р., Полушкин В.Г. С-реактивный белок как ранний маркер несостоятельности швов толстокишечного анастомоза после резекции толстой кишки по поводу рака. Систематический обзор и метаанализ. Хирургия. Журнал им. Н.И. Пирогова, 2020. № 8. С. 82–87.</mixed-citation><mixed-citation xml:lang="en">Lyadov V.K., Garipov M.R., Polushkin V.G. C-reactive protein as an early marker of colonic anastomotic suture failure after colon resection for cancer. Systematic review and meta-analysis. Pirogov Russian Journal of Surgery, 2020, № 8, pp. 82–87. (In Russian.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mohammad A., Ainio C., Narasimhulu D.M., McGree M., Weaver A.L., Kumar A., Garbi A., Mariani A., Aletti G., Multinu F., Langstraat C., Cliby W. Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction. International Journal of Gynecologic Cancer, 2023, № 33 (5). https://doi.org/10.1136/ijgc-2022-003962</mixed-citation><mixed-citation xml:lang="en">Mohammad A., Ainio C., Narasimhulu D.M., McGree M., Weaver A.L., Kumar A., Garbi A., Mariani A., Aletti G., Multinu F., Langstraat C., Cliby W. Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction. International Journal of Gynecologic Cancer, 2023\, № 33 (5). https://doi.org/10.1136/ijgc-2022-003962</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gerestein C.G., Damhuis R.A., Burger C.W., Kooi G.S. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecologic oncology, 2009. № 114 (3), рр. 523–527. https://doi.org/10.1016/j.ygyno.2009.03.011</mixed-citation><mixed-citation xml:lang="en">Gerestein C.G., Damhuis R.A., Burger C.W., Kooi G.S. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review.  Gynecologic oncology, 2009. №  114 (3), рр. 523–527. https://doi.org/10.1016/j.ygyno.2009.03.011</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Thrall M.M., Goff B.A., Symons R.G., Flum D.R., Gray H.J. Thirtyday mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstetrics &amp; Gynecology, 2011, № 118 (3), рр. 537–547. https://doi.org/10.1097/AOG.0b013e31822a6d56</mixed-citation><mixed-citation xml:lang="en">Thrall M.M., Goff B.A., Symons R.G., Flum D.R., Gray H.J. Thirtyday mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstetrics &amp; Gynecology, 2011, № 118 (3), рр. 537–547. https://doi.org/10.1097/AOG.0b013e31822a6d56</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Aletti G.D., Dowdy S.C., Podratz K.C., Cliby W.A. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American journal of obstetrics and gynecology, № 197 (6), рр. 676. https://doi.org/10.1016/j.ajog.2007.10.495</mixed-citation><mixed-citation xml:lang="en">Aletti G.D., Dowdy S.C., Podratz K.C., Cliby W.A. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American journal of obstetrics and gynecology, № 197 (6), рр. 676. https://doi.org/10.1016/j.ajog.2007.10.495</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Aletti G.D, Santillan A., Eisenhauer E.L., Hu J., Aletti G., Podratz K.C., Bristow R.E., Chi D.S., Cliby W.A. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecologic oncology, 2007, № 107 (1), рр. 99–106. https://doi.org/10.1016/j.ygyno.2007.05.032</mixed-citation><mixed-citation xml:lang="en">Aletti G.D, Santillan A., Eisenhauer E.L., Hu J., Aletti G., Podratz K.C., Bristow R.E., Chi D.S., Cliby W.A. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecologic oncology, 2007, № 107 (1), рр. 99–106. https://doi.org/10.1016/j.ygyno.2007.05.032</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cham S., Chen L., St Clair C.M., Hou J.Y., Tergas A.I., Melamed A., Ananth C.V., Neugut A.I., Hershman D.L., Wright J.D. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. American journal of obstetrics and gynecology, № 220 (6), рр. 571. https://doi.org/10.1016/j.ajog.2019.02.019</mixed-citation><mixed-citation xml:lang="en">Cham S., Chen L., St Clair C.M., Hou J.Y., Tergas A.I., Melamed A., Ananth C.V., Neugut A.I., Hershman D.L., Wright J.D. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. American journal of obstetrics and gynecology, № 220 (6), рр. 571. https://doi.org/10.1016/j.ajog.2019.02.019</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kabir T., Syn N.L., Tan Z.Z.X., Tan H.J., Yen C., Koh Y.X., Kam J.H., Teo J.Y., Lee S.Y., Cheow P.C., Chow P.K.H., Chung A.Y.F., Ooi L.L., Chan C.Y., Goh B.K.P. Predictors of post-operative complications after surgical resection of hepatocellular carcinoma and their prognostic effects on outcome and survival: a propensity-score matched and structural equation modelling study. European Journal of Surgical Oncology, 2020, № 46 (9), рр. 1756–1765. https://doi.org/10.1016/j.ejso.2020.03.219</mixed-citation><mixed-citation xml:lang="en">Kabir T., Syn N.L., Tan Z.Z.X., Tan H.J., Yen C., Koh Y.X., Kam J.H., Teo J.Y., Lee S.Y., Cheow P.C., Chow P.K.H., Chung A.Y.F., Ooi L.L., Chan C.Y., Goh B.K.P. Predictors of post-operative complications after surgical resection of hepatocellular carcinoma and their prognostic effects on outcome and survival: a propensity-score matched and structural equation modelling study. European Journal of Surgical Oncology, 2020, № 46 (9), рр. 1756–1765. https://doi.org/10.1016/j.ejso.2020.03.219</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Aeschbacher P., Nguyen T.L., Dorn P., Kocher G.J., Lutz J.A. Surgical site infections are associated with higher blood loss and open access in general thoracic practice. Frontiers in Surgery, 2021, № 8. https://doi.org/10.3389/fsurg.2021.656249</mixed-citation><mixed-citation xml:lang="en">Aeschbacher P., Nguyen T.L., Dorn P., Kocher G.J., Lutz J.A. Surgical site infections are associated with higher blood loss and open access in general thoracic practice. Frontiers in Surgery, 2021, № 8. https://doi.org/10.3389/fsurg.2021.656249</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
